The estimated Net Worth of Marsha Fanucci is at least $2.49 millió dollars as of 23 February 2023. Ms. Fanucci owns over 136 units of Alnylam Pharmaceuticals Inc stock worth over $35,620 and over the last 20 years she sold ALNY stock worth over $1,965,406. In addition, she makes $490,707 as Independent Director at Alnylam Pharmaceuticals Inc.
Marsha has made over 7 trades of the Alnylam Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently she exercised 136 units of ALNY stock worth $35,620 on 23 February 2023.
The largest trade she's ever made was exercising 75,000 units of Alnylam Pharmaceuticals Inc stock on 20 November 2019 worth over $1,035,000. On average, Marsha trades about 3,443 units every 62 days since 2005. As of 23 February 2023 she still owns at least 136 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Ms. Fanucci stock trades at the bottom of the page.
Marsha H. Fanucci is Independent Director of Alnylam Pharmaceuticals, Inc. Ms. Fanucci served as Senior Vice President and Chief Financial Officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company (now a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited), from July 2004 to January 2009. While at Millennium, she also served as Vice President, Finance and Corporate Strategy from July 2003 to June 2004, and prior to that as Vice President of Corporate Development from 2000. Prior to joining Millennium, Ms. Fanucci served as Vice President of Corporate Development and Strategy at Genzyme Corporation, a biotechnology company (now Sanofi Genzyme, the specialty care global business unit of Sanofi), from 1998 to 2000. Ms. Fanucci also serves as a director of Ironwood Pharmaceuticals, Inc. and Syros Pharmaceuticals, Inc., and formerly served as a director of Momenta Pharmaceuticals, Inc.
As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of Marsha Fanucci at Alnylam Pharmaceuticals Inc is $490,707. There are 14 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
Marsha Fanucci is 67, she's been the Independent Director of Alnylam Pharmaceuticals Inc since 2010. There are 2 older and 17 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
Marsha's mailing address filed with the SEC is C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal és Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: